NCT00344422: Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma |
|
|
| Completed | 3 | 198 | US | Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA | Multiple Myeloma, Myeloma, M-Protein, Myeloma Proteins | | 06/04 | | |
NCT00633542: Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) |
|
|
| Completed | 3 | 103 | Europe | thalidomide, interferon alpha | Università Politecnica delle Marche | Multiple Myeloma | 09/07 | 10/07 | | |
NCT00097981: A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma |
|
|
| Completed | 3 | 225 | US | Thalidomide, Dexamethasone, DOXIL | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA | Multiple Myeloma | 10/07 | 10/09 | | |
NCT00103506 / 2004-001842-34: Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma |
|
|
| Completed | 3 | 646 | US, Canada, Europe, RoW | Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX) | Janssen Research & Development, LLC | Multiple Myeloma | 05/14 | 06/14 | | |
